EUVIMEDEUVIMED entdecken
Crossref

Natural pachypodol integrated, lung targeted and inhaled lipid nanomedicine ameliorates acute lung injury via anti-inflammation and repairing lung barrier

Zhi-Chao Sun, Ran Liao, Caihong Xian, Ran Lin, Liying Wang, Yifei Fang, Zhongde Zhang, Yuntao Liu, Jun Wu

Journal of Controlled Release · 2024-11 · 375 · 300-315

DOI: 10.1016/j.jconrel.2024.09.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-11. Verfasst von Zhi-Chao Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 55 N, Neih…. Hauptthemen laut MEDLINE: Acute Lung Injury, Anti-Inflammatory Agents, Liposomes, Lung. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Traditional Chinese Medicine Bureau of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is a high-mortality disease caused by multiple disorders such as COVID-19, influenza, and sepsis. Current therapies mainly rely on the inhalation of nitric oxide or injection of pharmaceutical drugs (e.g., glucocorticoids); however, their toxicity, side effects, or administration routes limit their clinical application. In this study, pachypodol (Pac), a hydrophobic flavonol with anti-inflammatory effects, was extracted from Pogostemon cablin Benth and intercalated in liposomes (Pac@liposome, Pac-lipo) to improve its solubility, biodistribution, and bioavailability, aiming at enhanced ALI/ARDS therapy. Nanosized Pac-lipo was confirmed to have stable physical properties, good biodistribution, and reliable biocompatibility. In vitro tests proved that Pac-lipo has anti-inflammatory property and protective effects on endothelial and epithelial barriers in lipopolysaccharide (LPS)-induced macrophages and endothelial cells, respectively. Further, the roles of Pac-lipo were validated on treating LPS-induced ALI in mice. Pac-lipo showed better effects than did Pac alone on relieving ALI phenotypes: It significantly attenuated lung index, improved pulmonary functions, inhibited cytokine expression such as TNF-α, IL-6, IL-1β, and iNOS in lung tissues, alleviated lung injury shown by HE staining, reduced protein content and total cell number in bronchoalveolar lavage fluid, and repaired lung epithelial and vascular endothelial barriers. As regards the underlying mechanisms, RNA sequencing results showed that the effects of the drugs were associated with numerous immune- and inflammation-related signaling pathways. Molecular docking and western blotting demonstrated that Pac-lipo inhibited the activation of the TLR4-MyD88-NF-κB/MAPK signaling pathway. Taken together, for the first time, our new drug (Pac-lipo) ameliorates ALI via inhibition of TLR4-MyD88-NF-κB/MAPK pathway-mediated inflammation and disruption of lung barrier. These findings may provide a promising strategy for ALI treatment in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjuryAnti-Inflammatory AgentsLiposomesLungAnimalsAdministration, InhalationMaleMiceHumansMice, Inbred C57BLNanomedicineLipopolysaccharidesLamiaceaeRAW 264.7 CellsLipids

Stichwörter der Autor:innen

Acute lung injuryAnti-inflammationLiposomeLung barrierPachypodol

Substanzen

Anti-Inflammatory AgentsLiposomesLipopolysaccharidesLipids

Autor:innen und Institutionen

  • State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 55 N, Neihuanxi Road, Guangzhou 510006, Guangdong, China.
  • Bioscience and Biomedical Engineering Thrust, Systems Hub, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou 511400, Guangdong, China; School of Biomedical Engineering, Sun Yat-sen Univer…
  • State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 55 N, Neihuanxi Road, Guangzhou 510006, Guangdong, China. Electronic address: do…
  • State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 55 N, Neihuanxi Road, Guangzhou 510006, Guangdong, China. Electronic address: li…
  • Bioscience and Biomedical Engineering Thrust, Systems Hub, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou 511400, Guangdong, China; Division of Life Science, The Hong Kong University o…

Förderung

  • National Natural Science Foundation of China
  • Traditional Chinese Medicine Bureau of Guangdong Province

Zitieren

APA

Sun, Z. C., Liao, R., Xian, C., Lin, R., Wang, L., Fang, Y., Zhang, Z., Liu, Y., & Wu, J. (2024). Natural pachypodol integrated, lung targeted and inhaled lipid nanomedicine ameliorates acute lung injury via anti-inflammation and repairing lung barrier. Journal of Controlled Release, 375, 300-315. https://doi.org/10.1016/j.jconrel.2024.09.013

Vancouver

Sun ZC, Liao R, Xian C, Lin R, Wang L, Fang Y, et al. Natural pachypodol integrated, lung targeted and inhaled lipid nanomedicine ameliorates acute lung injury via anti-inflammation and repairing lung barrier. Journal of Controlled Release. 2024;375:300-315. doi:10.1016/j.jconrel.2024.09.013

BibTeX
@article{Sun2024,
  author = {Sun, Zhi-Chao and Liao, Ran and Xian, Caihong and Lin, Ran and Wang, Liying and Fang, Yifei and Zhang, Zhongde and Liu, Yuntao and Wu, Jun},
  title = {Natural pachypodol integrated, lung targeted and inhaled lipid nanomedicine ameliorates acute lung injury via anti-inflammation and repairing lung barrier},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {375},
  pages = {300--315},
  doi = {10.1016/j.jconrel.2024.09.013}
}
Kostenlos starten →